The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.
Category: GLP-1 RAs (Drug)
-
U.S. Announces Negotiated Prices for 15 Drugs Under Medicare
The Trump administration said that had the new prices been in effect last year, Medicare would have saved $12 billion, which would have reduced its spending on those drugs by 44 percent.
-
Ozempic Drug Fails to Quell Alzheimer’s in Novo Nordisk Trials
The studies were a significant setback for the optimistic view that semaglutide and other GLP-1 drugs could help prevent a number of brain diseases.
-
Eli Lilly, Drug Maker of Zepbound and Mounjaro, Reaches $1 Trillion in Value
The 150-year-old drugmaker is the first company in health care to hit the milestone.
-
Kennedy Walks a Tightrope on Trump Deal for Obesity Drugs
The weight loss medicines are proving to be a test case for Robert F. Kennedy Jr., the health secretary, in straddling divisions between his supporters and the president.
-
Pfizer to Acquire Obesity Drug Start-Up Metsera in $10 Billion Deal
The announcement of the deal signaled an end to the bidding war for Metsera between Pfizer and Novo Nordisk, the Danish maker of Ozempic and Wegovy.
-
What Trump’s New Drug Pricing Deal Means for People With Obesity
The president’s agreement with drug companies involves a range of prices, depending on dose, product and how you’re paying.
-
Obesity Drugs May Drop to as Little as $150 a Month
President Trump announced a deal with Eli Lilly and Novo Nordisk to lower prices on hugely popular weight-loss drugs for Medicare, Medicaid and American patients who pay with their own money.
-
Costco to Sell Ozempic and Wegovy, Weight-Loss Wonder Drugs
Costco members will pay $499 a month out of pocket, the same price offered at CVS and Walmart, and on the manufacturer’s direct-to-consumer website.
-
How Private Equity Oversees the Ethics of Drug Research
Many drug trials are vetted by companies with ties to the drugmakers, raising concerns about conflicts of interest and patient safety.
-
Pill Causes Major Weight Loss in Eli Lilly Trial’s Results
The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the year.
-
How Ozempic Maker Novo Nordisk Lost Its Shine
The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed its fortunes.